National Cervical Screening Program: Guidelines for the management of screen-detected abnormalities, screening in specific populations and investigation of abnormal vaginal bleeding

Cite this guideline

Cancer Council Australia Cervical Cancer Screening Guidelines Working Party. National Cervical Screening Program: Guidelines for the management of screen-detected abnormalities, screening in specific populations and investigation of abnormal vaginal bleeding. Sydney: Cancer Council Australia. [Version URL: https://wiki.cancer.org.au/australiawiki/index.php?oldid=174048, cited 2018 Aug 20]. Available from: https://wiki.cancer.org.au/australia/Guidelines:Cervical_cancer/Screening.

Endorsed by

Clinical management guidelines for the prevention of cervical cancer

3. Terminology

• HPV testing terminology

• Cytology and AMBS 2004 terminology for reporting cervical cytology

• Preparation of cervical screening reports

• Colposcopy

• Histopathology

• Supplement. Sample reports

6. Management of oncogenic HPV test results

• Medical Services Advisory Committee recommendations for HPV testing

• Oncogenic HPV types not detected

• Oncogenic HPV types 16 and/or 18

• HPV oncogenic types not 16/18

• Self-collected vaginal samples

• Women undergoing exit testing

• Screening in women older than 75

• Discussion

7. Colposcopy

• Colposcopy terminology

• Principles of practice

• History, examination and investigation

• Treatment

• Colposcopy data for the National Cancer Screening Register

• Quality improvement in colposcopy

• Supplement. Colposcopy information for discussion with patient

• Supplement. Colposcopy technologies and documentation

8. Management of discordant colposcopic impression, histopathology and referral LBC prediction

• Normal colposcopic findings following LBC prediction of LSIL or HSIL

• Type 3 TZ (unsatisfactory) colposcopy following LBC prediction of LSIL or HSIL

• Discussion

10. Management of histologically confirmed high-grade squamous abnormalities

• Diagnosis of HSIL

• Treatment of HSIL

• Test of Cure after treatment for HSIL (CIN2/3)

• Discussion

11. Management of glandular abnormalities

• Investigation of cytological glandular abnormalities

• Follow-up after excisional treatment for AIS

• Discussion

Appendices

• Appendix A. Modelled evaluation of the predicted benefits, harms and cost-effectiveness of the renewed National Cervical Screening Program (NCSP) in conjunction with these guideline recommendations
• Appendix B. Guidelines development process
• Appendix C. Clinical question list
• Appendix D. Technical report
• Appendix E. Working party members and contributors
• Appendix F. Project Team contributions
• Appendix G. Conflict of interest register
• Appendix H. Safety monitoring of the Renewed cervical screening program
• Appendix I. Glossary (terms and abbreviations)

Please see the Australian Department of Health Cancer Screening website for information about the National Cervical Screening Program (NCSPNational Cervical Screening ProgramA joint program of the Australian, state and territory governments. It aims to reduce morbidity and mortality from cervical cancer, in a cost-effective manner through an organised approach to cervical screening. The program encourages women in the target population to have regular Pap smears.) and policies on transitioning women to the renewed NCSPNational Cervical Screening ProgramA joint program of the Australian, state and territory governments. It aims to reduce morbidity and mortality from cervical cancer, in a cost-effective manner through an organised approach to cervical screening. The program encourages women in the target population to have regular Pap smears..

Resources

PDF download: National Cervical Screening Program guidelines

PDF download: National Cervical Screening Program short-form guidelines (recommendations only)

Cervical cancer screening online education modules (e-learning)

Back to top